In a groundbreaking development that may redefine our understanding of Alzheimer’s disease and its treatment, a team of researchers has uncovered a novel molecular pathway that could significantly improve cognitive functions and synaptic plasticity in affected individuals. The new study, published in Experimental & Molecular Medicine, reveals how HMGCS2-dependent β-hydroxybutyrate (β-OHB) and histone H3 lysine 9 β-hydroxybutyrylation (H3K9bhb) exert a protective role in Alzheimer’s pathology. This discovery underscores a potential therapeutic target for one of the most challenging neurodegenerative diseases plaguing millions worldwide.
Alzheimer’s disease, characterized by progressive memory loss, cognitive decline, and synaptic dysfunction, has long eluded effective curative therapies. The traditional focus on amyloid plaques and tau tangles has yielded important insights but has failed to produce definitive treatment outcomes. Now, the introduction of epigenetic regulation and metabolic modulators into Alzheimer’s research offers new hope. The enzyme 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) has been identified as a key metabolic regulator responsible for producing β-OHB, a ketone body that serves not only as an alternative energy substrate for neurons but also as a signaling molecule influencing chromatin modifications.
The team led by Yu, Wang, Yuan, et al., harnessed cutting-edge molecular techniques to investigate the interplay between HMGCS2 activity, β-OHB levels, and the epigenetic landscape in Alzheimer’s disease models. Their results demonstrate a remarkable enhancement in synaptic plasticity, the ability of neurons to strengthen or weaken synapses in response to activity, which is crucial for learning and memory. The researchers observed that upregulation of HMGCS2 boosted β-OHB production, which in turn triggered histone modification through β-hydroxybutyrylation specifically at lysine 9 on histone H3 (H3K9bhb).
This histone modification is notable because it alters chromatin structure, affecting gene accessibility without changing the DNA sequence, thereby fine-tuning gene expression in neurons. By promoting H3K9bhb, β-OHB facilitates the transcription of genes essential for synaptic function and neuroprotection. This epigenetic modulation operates as a vital link between cellular metabolism and gene regulation, ultimately influencing cognitive outcomes in Alzheimer’s disease models. It suggests that metabolic interventions that increase β-OHB could hold promise in restoring cognitive capacity.
Strikingly, the findings indicate that mice with Alzheimer’s-like symptoms showed remarkable cognitive improvements after treatment strategies aimed at enhancing the HMGCS2/β-OHB/H3K9bhb axis. This was evident in various behavioral assays measuring memory retention and learning abilities. Such results signify the pathway’s direct involvement in combating the synaptic degeneration typically observed in Alzheimer’s pathology. It also opens a new avenue where metabolic and epigenetic therapies converge, proposing a synergistic approach to neurodegeneration.
The biological implications of this study extend beyond the metabolic lens, touching on the broader theme of epigenetics in neurodegenerative diseases. Histone modifications have traditionally been investigated concerning cancer and developmental biology, but this research propels their relevance in neurology. The specific β-hydroxybutyrylation modification, which was only recently characterized, now emerges as a critical molecular mechanism governing neuronal gene expression and plasticity. The findings encourage a reevaluation of how ketone bodies are viewed—not just as metabolic fuels but as powerful epigenetic effectors that reshape neuronal function and resilience.
Furthermore, the study provides insights into how ketogenic diets or exogenous ketone supplements could be optimized to leverage this pathway therapeutically. Although ketogenic diets have been proposed in the management of certain neurological disorders, including epilepsy and neurodegeneration, their precise mechanisms remained unclear. This research clarifies part of that ambiguity by highlighting the molecular framework within which β-OHB interacts to induce beneficial chromatin modifications. It points toward precision dietary or pharmacological interventions designed to stimulate HMGCS2 activity or mimic β-OHB’s epigenetic effects as viable treatment options.
The researchers also shed light on how Alzheimer’s disease fundamentally disrupts this metabolic-epigenetic crosstalk, leading to diminished β-OHB production and impaired H3K9bhb signaling. This disruption contributes to synaptic failure and cognitive deficits, presenting a self-perpetuating cycle of metabolic dysfunction and epigenetic dysregulation. Restoring this signaling circuit could counteract the disease’s progression, potentially halting or reversing cognitive decline.
From a therapeutic development perspective, targeting HMGCS2 presents unique challenges but also tantalizing opportunities. The enzyme is a mitochondrial protein playing an integral role in ketogenesis, making it a strategic metabolic node for intervention. Pharmacological enhancers or gene therapy approaches to boost HMGCS2 expression in the brain could enhance local β-OHB production, thereby promoting neuroprotective epigenetic modifications. However, targeted delivery and safety profiles must be meticulously addressed in subsequent clinical development phases.
In addition to experimental mouse models, the study incorporated human-derived neuronal cultures, providing translational relevance to the findings. The consistent observation of H3K9bhb elevation following β-OHB supplementation in human neurons corroborates the potential applicability of these mechanisms in patients. This strengthens the prospect that metabolic regulation of epigenetics via the HMGCS2/β-OHB axis could represent a universal strategy to enhance cognitive resilience despite neurodegenerative challenges.
Interestingly, the study also situates itself within the broader context of metabolic aging and neurodegeneration research, where shifts in energy metabolism profoundly affect brain function. Alzheimer’s disease can no longer be seen purely as a proteinopathy but rather as a metabolic breakdown compounded by epigenetic maladaptations. The identification of β-hydroxybutyrylation as a driver of gene expression changes linked to synaptic plasticity firmly integrates metabolism, epigenetics, and neuronal health into a cohesive pathogenic framework.
Crucially, these novel insights suggest biomarkers that could be harnessed for clinical diagnosis and progression monitoring in Alzheimer’s disease. Measurements of β-OHB levels or H3K9bhb status in cerebrospinal fluid or blood could provide valuable indicators of disease stage or response to metabolic interventions. This might pave the way for less invasive and more dynamic monitoring tools than current imaging or cognitive assessments.
Looking ahead, the research team encourages continued exploration of the metabolic-epigenetic nexus in neurodegeneration. Further elucidation of other histone modifications influenced by ketone bodies and their impact on neuroinflammation, oxidative stress, and neuronal survival will deepen our comprehension of Alzheimer’s pathogenesis. Additionally, clinical trials assessing the efficacy of β-OHB–increasing therapies, whether dietary, pharmaceutical, or gene-based, will be critical to translating these laboratory breakthroughs into real-world treatments that improve patient quality of life.
This paradigm shift offered by the HMGCS2-dependent β-OHB/H3K9bhb axis heralds a new frontier in Alzheimer’s research. By illuminating how metabolism directly controls gene regulation to support synaptic integrity and cognitive function, this study provides a promising beacon in the quest for effective interventions against this relentless disease. The future of Alzheimer’s treatment may well hinge on unraveling and harnessing the full therapeutic potential of metabolic epigenetic modulation as revealed by this transformative research.
Subject of Research: Alzheimer’s disease, synaptic plasticity, cognitive function, metabolic-epigenetic regulation
Article Title: HMGCS2-dependent β-OHB/H3K9bhb ameliorates synaptic plasticity and cognition in Alzheimer’s disease
Article References:
Yu, H., Wang, F., Yuan, Jq. et al. HMGCS2-dependent β-OHB/H3K9bhb ameliorates synaptic plasticity and cognition in Alzheimer’s disease. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01664-9
Image Credits: AI Generated
DOI: 10.1038/s12276-026-01664-9 (06 March 2026)
Tags: Alzheimer’s cognitive function improvementchromatin modification and neuroprotectionepigenetic regulation in Alzheimer’s therapyhistone H3K9bhb epigenetic modificationHMGCS2 in Alzheimer’s diseaseketone bodies and brain metabolismmetabolic modulation for neurodegenerative diseasesmolecular pathways in Alzheimer’s treatmentnovel therapeutic targets for Alzheimer’s diseasesynaptic plasticity enhancement in neurodegenerationβ-hydroxybutyrate neuroprotectionβ-OHB as neuronal signaling molecule
